CliffBio
small molecule

ABACAVIR SULFATE AND LAMIVUDINE

ABACAVIR SULFATE; LAMIVUDINE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameABACAVIR SULFATE AND LAMIVUDINE
Active ingredientABACAVIR SULFATE; LAMIVUDINE
StrengthEQ 600MG BASE;300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2017
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ABACAVIR SULFATE AND LAMIVUDINE patent cliff — loss of exclusivity — | CliffBio